Though the specific targeting ability to HER2 was not validated at the molecular or cellular level in an subcutaneous tumor model, the synthesized nanoMIP could specifically target ovarian cancer, as evidenced by the higher DOX concentration in the tumor tissues, enhanced antitumor efficacy, and prolonged survival of mice. Here, ERBB2 is linked to neoplasm.